WallStSmart

Kimberly-Clark Corporation (KMB)vsSRx Health Solutions Inc. (SRXH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kimberly-Clark Corporation generates 177140% more annual revenue ($16.56B vs $9.34M). KMB leads profitability with a 12.8% profit margin vs 0.0%. KMB earns a higher WallStSmart Score of 63/100 (C+).

KMB

Buy

63

out of 100

Grade: C+

Growth: 4.7Profit: 8.0Value: 4.0Quality: 4.0
Piotroski: 3/9Altman Z: 2.19

SRXH

Avoid

16

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 4.0
Piotroski: 2/9Altman Z: -4.74
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KMBSignificantly Overvalued (-19.0%)

Margin of Safety

-19.0%

Fair Value

$90.45

Current Price

$98.43

$7.98 premium

UndervaluedFair: $90.45Overvalued

Intrinsic value data unavailable for SRXH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KMB1 strengths · Avg: 10.0/10
Return on EquityProfitability
111.7%10/10

Every $100 of equity generates 112 in profit

SRXH0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

KMB4 concerns · Avg: 3.3/10
PEG RatioValuation
1.994/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
21.7x2/10

Trading at 21.7x book value

SRXH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$55.45M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : KMB

The strongest argument for KMB centers on Return on Equity.

Bull Case : SRXH

SRXH has a balanced fundamental profile.

Bear Case : KMB

The primary concerns for KMB are PEG Ratio, Revenue Growth, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.

Bear Case : SRXH

The primary concerns for SRXH are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 10.99 is elevated, increasing financial risk.

Key Dynamics to Monitor

KMB is growing revenue faster at 2.7% — sustainability is the question.

KMB generates stronger free cash flow (575M), providing more financial flexibility.

Monitor HOUSEHOLD & PERSONAL PRODUCTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KMB scores higher overall (63/100 vs 16/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kimberly-Clark Corporation

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.

Visit Website →

SRx Health Solutions Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

SRx Health Solutions Inc. provides healthcare and medical treatment services.

Visit Website →

Want to dig deeper into these stocks?